The INNOVATE Act edits section 9 of the Small Business Act to push SBIR/STTR away from purely early‑stage R&D toward faster technology transition and commercialization, while also expanding access for new entrants and hardening research‑security controls. It creates a new pathway for larger, transition‑focused Phase II awards, adds a brief low‑barrier Phase 1A for first‑time applicants, and adjusts program benchmarks and data requirements.
The bill also tightens due diligence and post‑award recovery authority to limit adversarial foreign influence, requires most SBIR/STTR contracts to be firm‑fixed‑price by default, and instructs agencies to collect and share more detailed program data. For program managers, investors, and compliance officers, the package is both an operational acceleration and a new compliance regime: larger transition dollars plus stricter foreign‑risk screening and longer post‑award restrictions on IP transfers.
At a Glance
What It Does
It creates a Department of Defense 'strategic breakthrough' allocation (a statutory minimum of 0.25% of DoD extramural R&D) that lets DoD award up to $30 million to a single small business under Phase II for transition activities; it mandates a Phase 1A small‑award track to draw first‑time applicants and raises set‑asides for STTR. The bill defaults SBIR/STTR contracts to firm‑fixed‑price and layers in new reporting and data fields.
Who It Affects
Small businesses across defense and civilian SBIR/STTR portfolios, DoD program offices and acquisition organizations, university partners (STTR), commercial investors and VC limited partners, agency CFOs and contracting officers, and compliance/counterintelligence teams that run due diligence.
Why It Matters
It shifts the programs’ incentives from repeated early‑stage awards toward fewer, larger transition investments and measurable commercialization outcomes, while coupling that shift with mandatory security screening and new administrative/reporting duties that could reshape who gets funded and how awards are structured.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The INNOVATE Act repackages the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs with three parallel objectives: accelerate transition of “battle‑ready” technologies into acquisition, increase participation from new entrants and under‑served geographies, and protect U.S. innovation from adversarial foreign influence. To do that, it layers new award categories and eligibility rules on top of the existing section 9 framework of the Small Business Act.
For transition, the bill gives DoD a dedicated ‘strategic breakthrough’ allocation (a minimum share of its SBIR set‑aside) and authority to make very large Phase II awards without the usual waiver process. Those awards are explicitly for transition tasks (manufacturing, testing, certification, purchase of low‑rate production units, supply‑chain establishment and design for manufacturing) and can reach up to $30 million for a single recipient with a multi‑year performance period.
DoD must tie selection to program office intent (program executive officer or higher) and market research showing the solution meets a real need.To expand the funnel, the bill creates a Phase 1A: a short, low‑barrier award (small dollar amount) reserved for first‑time SBIR/STTR applicants, funded from an agency set‑aside. It also changes size and participation caps so very large serial SBIR/STTR recipients face limits on applying, and it restricts who may be a primary investigator on simultaneous proposals.On security, the bill defines a broad concept of 'foreign risk' and requires agencies’ due diligence programs to check applicants against an enumerated set of government lists (Commerce Entity List, DoD/Defense‑industry lists, OFAC lists, FCC equipment lists, CBP Withhold Release Orders, and others).
It expands agency authority to recover awards or restrict transfers of IP developed with SBIR/STTR funds for multi‑year periods and requires better documentation of adverse findings. The Administration and agencies must produce best practices for investor informational rights to reduce inadvertent sharing of sensitive IP with foreign partners.Operationally, the Act pushes agencies to use firm‑fixed‑price contracts for SBIR/STTR awards by default, requires additional data fields in SBIR databases and in FPDS to track Phase 1A, direct‑to‑Phase II, strategic breakthrough awards, and Phase III prime/subcontracts, tightens solicitation rules (definition of 'open topic'), and caps how many proposals a firm may submit to a single solicitation and per agency per year.
It also extends authorization deadlines for the programs and instructs GAO to annually review due diligence practices for several years.
The Five Things You Need to Know
DoD strategic breakthrough awards: a company may receive a single award up to $30,000,000 (max 48‑month performance) from the dedicated strategic allocation; DoD must complete award actions within 90 days of receiving a proposal.
Phase 1A: agencies must allocate at least 2.5% of their SBIR budget to short, $40,000‑cap Phase 1A awards that are available only to firms that have never before received an SBIR/STTR award.
Direct‑to‑Phase II limits: agencies generally may use this authority for up to 10% of their SBIR funds in a year (30% for NIH and DoD components) and cannot award direct‑to‑Phase II to firms that have already received more than 25 Phase II awards.
Expanded post‑award recovery windows: agencies may bar or recover awards where IP developed with SBIR/STTR funds is transferred to a foreign country of concern for up to 5 years (for certain IP transfers) or 10 years for other specified conditions, with amounts adjusted for inflation.
Data and procurement tracking: the bill requires new SBIR database fields and FPDS updates so each award/contract can be tagged as Phase 1A, direct‑to‑Phase II, subsequent Phase II, strategic breakthrough, Phase III prime, or Phase III subcontract for downstream analytics and oversight.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
STTR prioritization and budget shares
This provision adjusts STTR language to emphasize using STTR for fundamental research that benefits from partnerships with research institutions, and it increases minimum set‑aside percentages in the statute. Practically, agencies—especially DoD and NASA—are directed to use STTR funds for low technology readiness levels (1–3). For agency program managers, this channels STTR toward early science partnerships and reserves SBIR for later commercial transition tasks.
Large, transition‑focused Phase II awards and DoD allocation
This is the bill’s operational pivot: it creates a statutory 'strategic breakthrough allocation' for DoD (a floor on spending within the SBIR allocation) and allows a single Phase II award up to $30 million from that pool without a waiver. The provision sets eligibility gates (prior Phase II award required; cumulative DoD awards cap; 100% new matching funds requirement) and a menu of eligible transition activities from manufacturing setup to purchase of production units. It also mandates DoD acquisition offices provide program office commitments and requires DoD to integrate SBIR awardees into budget and program planning.
Default to firm‑fixed‑price contracts
The statute now directs funding agreements funded from SBIR or STTR allocations to be firm‑fixed‑price contracts unless the agency head makes a written, case‑by‑case determination otherwise. For contracting officers and small businesses, this shifts financial risk onto performers and changes budgeting, accounting, and pricing approaches for awards that previously used cost‑reimbursement models.
New entrant rules, Phase 1A, and anti‑discrimination reframing
The bill creates a Phase 1A program (short applications, small awards, 2.5% set‑aside) exclusively for firms that have never held SBIR/STTR awards to expand the applicant pool. It also implements applicant ceilings (firms that have received >$75M in Phase I/II awards cannot apply) and a Phase I size cap tied to annual receipts. Simultaneously it recasts program outreach from race/gender categories toward geographic 'emerging States' and rural areas, and bars agencies from considering race, gender, or ethnicity or using diversity statements in award decisions when using certain allocated funds.
Open topic definition and administrative limits
The bill defines 'open topic announcement' to mean generalized problem statements rather than tightly prescriptive specs, aiming to encourage novel solutions. It also caps how many proposals a firm may submit: no more than 3 proposals to a single solicitation and a combined total cap per agency (25 submissions per fiscal year), reducing administrative load on reviewers while constraining high‑volume applicants.
Foreign risk, enhanced due diligence, and recovery authority
Title IV defines 'foreign risk' broadly (foreign affiliations, investments, joint research, licensing, contractual ties) and requires agencies to evaluate applicants against specified government lists (Entity List, OFAC lists, FCC lists, DoD lists, etc.). It strengthens the due diligence program, authorizes agencies to deny awards for foreign risk, prohibits pre‑award communications that a denial is for foreign risk, and extends periods during which IP transfers to foreign entities can trigger recovery actions. The bill also mandates best practice guidance on investor informational rights and commissions GAO to audit agency due diligence practices.
Commercialization benchmarks, direct‑to‑Phase II, data, and program administration
The Act raises commercialization/transition performance targets for repeat winners (ratios of Phase II-to‑Phase I awards and revenue thresholds tied to private/commercial receipts), limits program participation for firms that fail benchmarks, expands direct‑to‑Phase II authority but caps its annual use by agency, and requires new SBIR data fields and FPDS tags so agencies can track types of awards (Phase 1A, direct‑to‑Phase II, strategic breakthrough, phase III prime/subcontract). It also extends SBIR/STTR authorization dates and makes assorted administrative cleanups.
This bill is one of many.
Codify tracks hundreds of bills on Technology across all five countries.
Explore Technology in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- First‑time and small early‑stage firms: Phase 1A creates a low‑barrier entry path with a small award and simplified application, increasing exposure to agency solicitations and lowering the cost of testing an idea.
- DoD program and acquisition offices: The strategic breakthrough pool provides a direct, funded mechanism to accelerate promising SBIR tech into programs of record and to fund manufacturing and certification activities that most SBIR awards do not cover.
- Agencies and oversight bodies seeking measurable outcomes: New commercialization benchmarks and richer award tagging improve the ability to measure transition success and to direct limited SBIR dollars to solutions with acquisition traction.
- National security and counterintelligence communities: Expanded due diligence checks and extended recovery windows give agencies clearer statutory tools to deny awards or recover value where foreign‑adversary ties or inappropriate transfers of IP are present.
Who Bears the Cost
- Serial SBIR/STTR recipients and high‑volume applicants: Tightened caps, new minimum commercialization benchmarks, and limits on direct‑to‑Phase II eligibility penalize firms that rely heavily on repeat awards without building commercial revenue.
- Small businesses with legitimate foreign collaboration or international investors: The broadened 'foreign risk' definition and mandatory checks against multiple government lists raise the risk of false positives and award denials, increasing compliance burden and legal risk.
- Agency acquisition, contracting, and program offices: Implementing strategic allocations, performing the new screening, changing contract vehicles to firm‑fixed‑price by default, and updating data systems (SBIR database and FPDS) will require staff time and possibly new budget allocations.
- Venture capital and investors: New guidance on investor informational rights and heightened scrutiny of LP rights may require renegotiation of term‑sheets or more formalized IP protection measures, potentially slowing deal timelines.
Key Issues
The Core Tension
The central dilemma is straightforward but stark: accelerate and fund real‑world transition of national‑security technology (which favors fewer, larger, acquisition‑oriented awards and tighter controls) or preserve the open, high‑risk, inclusive early‑stage innovation pipeline that accepts failure and global collaboration. The INNOVATE Act tries to do both by reallocating funds to transition and tightening security screens—but doing so inevitably raises barriers that can exclude the very experimental entrants and international collaborations that historically fueled disruptive breakthroughs.
Two core implementation challenges stand out. First, the bill ties larger transition awards to quick contracting timelines and acquisition commitments, but those same acquisition offices historically operate on different budget and schedule cadences than R&D programs.
DoD’s 90‑day award deadline and requirement for program executive officer commitment will force tighter coordination; absent additional resourcing, that could generate bottlenecks, rushed procurements, or selection decisions driven more by program politics than technical readiness.
Second, the security regime expands screening and recovery authority using multiple interagency lists and a broad statutory 'foreign risk' definition. That breadth reduces adversary loopholes but increases false positives and legal ambiguity.
Firms with benign ties (co‑authorships, diaspora investors, or basic academic collaborations) may trigger flags. Agencies must pick operational thresholds and adjudication processes; poor calibration risks excluding useful partners and chilling international collaborations.
The bill also increases administrative and IT requirements—FPDS/SBIR database changes and extra briefings/GAO studies—without explicit new appropriations for implementation, which could shift costs to operating units or slow rollout.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.